Chlorinated Monocarbonyl Curcumin for Stability and Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Curcumin's weak stability, poor solubility, and low bioavailability limit its clinical application for treating inflammation-related diseases, and there is a lack of compounds that significantly improve solubility and biological activity.
Innovation Solution
Synthesis of chlorinated monocarbonyl curcumin compounds by replacing the unstable β-dicarbonyl structure with monocarbonyl and introducing liposoluble groups, enhancing pharmacokinetic behavior and anti-inflammatory and antioxidant activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If curcumin is used to treat inflammation-related diseases, then anti-inflammatory and antioxidant activity is achieved, but stability and solubility are poor
Solution Approach 1:
The patent changes the chemical structure parameters of curcumin by replacing the β-dicarbonyl structural unit with a monocarbonyl unit, and introduces chlorinated groups at specific positions (3,5-dichloro substitution). This structural parameter modification resolves the contradiction by improving stability while maintaining solubility and biological activity.
Solution Approach 2:
The patent creates a composite molecular structure combining chlorinated aromatic rings with monocarbonyl curcumin framework. This composite approach integrates the stability-enhancing chlorinated groups with the bioactive curcumin core, achieving both improved stability and retained anti-inflammatory activity.
2Reliability
If curcumin is used for treatment, then biological activity is achieved, but solubility and bioavailability are low
Solution Approach 1:
The patent modifies solubility parameters by introducing chlorinated groups and changing the carbonyl structure from β-dicarbonyl to monocarbonyl. These parameter changes improve aqueous solubility and bioavailability while preserving the essential biological activity for treating inflammation-related diseases.
3Reliability
If β-dicarbonyl structure is present in curcumin, then pharmacological activity is maintained, but instability and irregular metabolism occur
Solution Approach 1:
The patent changes the metabolic stability parameter by replacing the β-dicarbonyl structural unit with a monocarbonyl unit. This structural parameter modification leads to more regular metabolism and improved stability while maintaining the pharmacological activity necessary for treating inflammation-related diseases.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chlorinated monocarbonyl curcumin compounds exhibit improved solubility, stability, and biological activity, offering potential anti-inflammatory and antioxidant drugs for treating a variety of inflammation-related diseases.
Implementation Method 1
Dissolving 2-10 parts of 3,5-dichloro-4-hydroxybenzaldehyde and 1-5 parts of 4-piperidone in 15-50 parts of saturated hydrogen chloride glacial acetic acid solution, and stirring at 22-28° C. for 12-24 h to obtain solution A
Data Source
AI summary
Chlorinated monocarbonyl curcumin compounds, a preparation method, and an application are provided. 3,5-dichloro-4-hydroxybenzaldehyde, 3-chloro-4-hydroxy-5-methoxybenzaldehyde, 4-piperidone, 1-methyl-4-piperidone, 1-ethyl-4-piperidone and 1-isopropyl-4-piperidone are used as raw materials, the unstable β-dicarbonyl structure of curcumin is substituted by monocarbonyl group, and chlorine substitution is carried out at the corresponding position of the benzene ring to obtain more stable monocarbonyl curcumin compounds CAK01-CAK07, which can improve the solubility and biological activity of curcumin at the same time, so that it has higher safety, better pharmacokinetic behavior and higher anti-inflammatory and antioxidant activity, the curcumin compounds are used to prepare drugs for the treatment of inflammation-related diseases.